Role of 131I-Metaiodobenzylguanidine in the treatment of neuroblastoma

R. Mastrangelo, Assunta Tornesello, Stefano Mastrangelo, S. Heyman, R. Mastrangelo, Assunta Tornesello, S. Mastragelo

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Background. Standard chemo-radiotherapy methods for the treatment of children with advanced neuroblastoma (NBL) including bone marrow transplant approaches have been disappointing. These poor results can be ascribed to the evolution of residual drug-resistant cell populations. Curative attempts should therefore be directed to their elimination during induction treatment. This can best be accomplished through the use of multiple, non-cross- resistant agents early in therapy. 131I-Metaiodobenzylguanidine (131I- MIBG) provides a mechanism for the delivery of high doses of radiation to NBL lesions. Experience reported from several institutions indicates an approximate 50% response rate in previously treated children with advanced NBL. Conclusions. A better strategy is to employ 131I-MIBG together with intensive chemotherapy at the time of diagnosis. A pilot study adopting these principles and supported by laboratory data has been designed and is underway.
Lingua originaleEnglish
pagine (da-a)22-26
Numero di pagine5
RivistaMedical and Pediatric Oncology
Volume31
DOI
Stato di pubblicazionePubblicato - 1998

Keywords

  • 131
  • Neuroblastoma
  • Multidrug chemotherapy
  • I-metaiodobenzylguanidine

Fingerprint

Entra nei temi di ricerca di 'Role of 131I-Metaiodobenzylguanidine in the treatment of neuroblastoma'. Insieme formano una fingerprint unica.

Cita questo